French drugmaker Sanofi (Euronext: SAN) has announced the availability of its new Pompe disease drug Nexviadyme (avalglucosidase alfa) on the UK’s National Health Service (NHS).
This offers patients a new long-term enzyme replacement therapy that has been recommended by cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE).
"Another critical milestone in Sanofi’s 20-year commitment to the Pompe community"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze